{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:49:14Z","timestamp":1794044954357,"version":"4.8.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-69538-2","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T09:04:45Z","timestamp":1771319085000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Adoptive \u03b3\u03b4 T cell therapy controls cytomegalovirus infection in preclinical transplantation models"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9200-2454","authenticated-orcid":false,"given":"Gabriel","family":"Mars\u00e8res","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coline","family":"Gentil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Tinevez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Courant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Cosentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Cornillot-Cl\u00e9ment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Bigot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Pitard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atika","family":"Zouine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Izotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Garrigue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Prouzet-Mauleon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2235-8540","authenticated-orcid":false,"given":"B\u00e9atrice","family":"Turcq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5793-6174","authenticated-orcid":false,"given":"Dany","family":"Anglicheau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8873-2868","authenticated-orcid":false,"given":"Edouard","family":"Forcade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1604-3825","authenticated-orcid":false,"given":"Hannah","family":"Kaminski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4141-9302","authenticated-orcid":false,"given":"Bruno","family":"Silva-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Merville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Capone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7521-9531","authenticated-orcid":false,"given":"Julie","family":"D\u00e9chanet-Merville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9213-6196","authenticated-orcid":false,"given":"Lionel","family":"Couzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"69538_CR1","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1111\/j.1600-6143.2010.03074.x","volume":"10","author":"A Humar","year":"2010","unstructured":"Humar, A. et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am. J. Transplant. 10, 1228\u20131237 (2010).","journal-title":"Am. J. Transplant."},{"key":"69538_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/TP.0b013e318238dab3","volume":"93","author":"O Witzke","year":"2012","unstructured":"Witzke, O. et al. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Transplantation 93, 61\u201368 (2012).","journal-title":"Transplantation"},{"key":"69538_CR3","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/j.1600-6143.2007.02133.x","volume":"8","author":"V Kliem","year":"2008","unstructured":"Kliem, V. et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am. J. Transplant. 8, 975\u2013983 (2008).","journal-title":"Am. J. Transplant."},{"key":"69538_CR4","doi-asserted-by":"crossref","unstructured":"Kotton, C. N. et al. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 102, 900\u2013931 (2018).","DOI":"10.1097\/TP.0000000000002191"},{"key":"69538_CR5","doi-asserted-by":"publisher","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","volume":"19","author":"P Ljungman","year":"2019","unstructured":"Ljungman, P. et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect. Dis. 19, e260\u2013e272 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"69538_CR6","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1097\/TP.0000000000001338","volume":"101","author":"Y Natori","year":"2017","unstructured":"Natori, Y. et al. Recurrence of CMV infection & the effect of prolonged antivirals in organ transplant recipients. Transplantation 101, 1449\u20131454 (2017).","journal-title":"Transplantation"},{"key":"69538_CR7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.hoc.2010.11.011","volume":"25","author":"P Ljungman","year":"2011","unstructured":"Ljungman, P., Hakki, M. & Boeckh, M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol. Oncol. Clin. North Am. 25, 151\u2013169 (2011).","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"69538_CR8","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1600-6143.2011.03766.x","volume":"12","author":"L Couzi","year":"2012","unstructured":"Couzi, L. et al. High incidence of anticytomegalovirus drug resistance among D+R-kidney transplant recipients receiving preemptive therapy. Am. J. Transplant. 12, 202\u2013209 (2012).","journal-title":"Am. J. Transplant."},{"key":"69538_CR9","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1093\/cid\/ciab988","volume":"75","author":"RK Avery","year":"2022","unstructured":"Avery, R. K. et al. Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial. Clin. Infect. Dis. 75, 690\u2013701 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"69538_CR10","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/infdis\/jiad293","volume":"229","author":"S Chou","year":"2024","unstructured":"Chou, S. et al. Drug resistance assessed in a phase 3 clinical trial of maribavir therapy for refractory or resistant cytomegalovirus infection in transplant recipients. J. Infect. Dis. 229, 413\u2013421 (2024).","journal-title":"J. Infect. Dis."},{"key":"69538_CR11","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1093\/cid\/ciz1210","volume":"71","author":"RF Chemaly","year":"2020","unstructured":"Chemaly, R. F. et al. Cytomegalovirus (CMV) cell-mediated immunity and cmv infection after allogeneic hematopoietic cell transplantation: the REACT study. Clin. Infect. Dis. 71, 2365\u20132374 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"69538_CR12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2217\/imt.14.99","volume":"7","author":"E Nicholson","year":"2015","unstructured":"Nicholson, E. & Peggs, K. S. Cytomegalovirus-specific T-cell therapies: current status and future prospects. Immunotherapy 7, 135\u2013146 (2015).","journal-title":"Immunotherapy"},{"key":"69538_CR13","doi-asserted-by":"crossref","unstructured":"Houghtelin, A. & Bollard, C. M. Virus-specific T cells for the immunocompromised patient. Front. Immunol. 8, 1272 (2017).","DOI":"10.3389\/fimmu.2017.01272"},{"key":"69538_CR14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI165476","volume":"133","author":"SE Prockop","year":"2023","unstructured":"Prockop, S. E. et al. Third-party cytomegalovirus-specific T cells improved survival in refractory cytomegalovirus viremia after hematopoietic transplant. J. Clin. Investig. 133, e165476 (2023).","journal-title":"J. Clin. Investig."},{"key":"69538_CR15","doi-asserted-by":"publisher","unstructured":"Khoury, R. et al. Third-party virus specific T cells for the treatment of double stranded DNA viral reactivation and PTLD after solid organ transplant. Am. J. Transplant. 24, 1634\u20131643 https:\/\/doi.org\/10.1016\/j.ajt.2024.04.009. (2024).","DOI":"10.1016\/j.ajt.2024.04.009"},{"key":"69538_CR16","doi-asserted-by":"publisher","unstructured":"Smith, C. et al. Autologous adoptive T-cell therapy for recurrent or drug-resistant cytomegalovirus complications in solid organ transplant recipients: a single-arm open-label phase I clinical trial. Clin. Infect. Dis. 68, 632\u2013640 https:\/\/doi.org\/10.1093\/cid\/ciy549. (2018).","DOI":"10.1093\/cid\/ciy549"},{"key":"69538_CR17","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.1172\/JCI128323","volume":"129","author":"C Smith","year":"2019","unstructured":"Smith, C. et al. T cell repertoire remodeling following post-transplant T cell therapy coincides with clinical response. J. Clin. Investig. 129, 5020\u20135032 (2019).","journal-title":"J. Clin. Investig."},{"key":"69538_CR18","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/imr.12922","volume":"298","author":"H Kaminski","year":"2020","unstructured":"Kaminski, H. et al. Understanding human \u03b3\u03b4 T cell biology toward a better management of cytomegalovirus infection. Immunol. Rev. 298, 264\u2013288 (2020).","journal-title":"Immunol. Rev."},{"key":"69538_CR19","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/imr.12927","volume":"298","author":"L Shen","year":"2020","unstructured":"Shen, L. et al. Fast-acting \u03b3\u03b4 T-cell subpopulation and protective immunity against infections. Immunol. Rev. 298, 254\u2013263 (2020).","journal-title":"Immunol. Rev."},{"key":"69538_CR20","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1111\/febs.15494","volume":"288","author":"A Pamplona","year":"2021","unstructured":"Pamplona, A. & Silva-Santos, B. \u03b3\u03b4 T cells in malaria: a double-edged sword. FEBS J. 288, 1118\u20131129 (2021).","journal-title":"FEBS J."},{"key":"69538_CR21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/2162-3619-2-14","volume":"2","author":"I Prinz","year":"2013","unstructured":"Prinz, I. et al. Donor V\u03b41+ \u03b3\u03b4 T cells expand after allogeneic hematopoietic stem cell transplantation and show reactivity against CMV-infected cells but not against progressing B-CLL. Exp. Hematol. Oncol. 2, 2\u20135 (2013).","journal-title":"Exp. Hematol. Oncol."},{"key":"69538_CR22","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1172\/JCI5409","volume":"103","author":"J D\u00e9chanet","year":"1999","unstructured":"D\u00e9chanet, J. et al. Implication of \u03b3\u03b4 T cells in the human immune response to cytomegalovirus. J. Clin. Investig. 103, 1437\u20131449 (1999).","journal-title":"J. Clin. Investig."},{"key":"69538_CR23","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1111\/j.1432-2277.2010.01181.x","volume":"24","author":"L Couzi","year":"2011","unstructured":"Couzi, L. et al. Gamma-delta T cell expansion is closely associated with cytomegalovirus infection in all solid organ transplant recipients. Transpl. Int. 24, e40\u2013e42 (2011).","journal-title":"Transpl. Int."},{"key":"69538_CR24","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1182\/blood-2008-01-136713","volume":"112","author":"V Pitard","year":"2008","unstructured":"Pitard, V. et al. Long-term expansion of effector\/memory V\u03b42\u2212 \u03b3\u03b4 T cells is a specific blood signature of CMV infection. Blood 112, 1317\u20131324 (2008).","journal-title":"Blood"},{"key":"69538_CR25","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1084\/jem.20041851","volume":"201","author":"F Halary","year":"2005","unstructured":"Halary, F. et al. Shared reactivity of V\u03b42 neg \u03b3\u03b4 T cells against cytomegalovirus-infected cells and tumor intestinal epithelial cells. J. Exp. Med. 201, 1567\u20131578 (2005).","journal-title":"J. Exp. Med."},{"key":"69538_CR26","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1182\/blood-2011-06-363655","volume":"119","author":"L Couzi","year":"2012","unstructured":"Couzi, L. et al. Antibody-dependent anti-cytomegalovirus activity of human gd T cells expressing CD16 (FcgRIIIa). Blood 119, 1418\u20131427 (2012).","journal-title":"Blood"},{"key":"69538_CR27","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1681\/ASN.2014100985","volume":"27","author":"H Kaminski","year":"2016","unstructured":"Kaminski, H. et al. Surveillance of \u03b3\u03b4 T cells predicts cytomegalovirus infection resolution in kidney transplants. J. Am. Soc. Nephrol. 27, 637\u2013645 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"69538_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.ppat.1004702","volume":"11","author":"C Khairallah","year":"2015","unstructured":"Khairallah, C. et al. \u03b3\u03b4 T cells confer protection against murine cytomegalovirus (MCMV). PLoS Pathog 11, 1\u201322 (2015).","journal-title":"PLoS Pathog"},{"key":"69538_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.ppat.1004481","volume":"11","author":"S Sell","year":"2015","unstructured":"Sell, S. et al. Control of murine cytomegalovirus infection by \u03b3\u03b4 T cells. PLoS Pathog 11, 1\u201321 (2015).","journal-title":"PLoS Pathog"},{"key":"69538_CR30","doi-asserted-by":"publisher","first-page":"5795","DOI":"10.1158\/1078-0432.CCR-16-0597","volume":"22","author":"AR Almeida","year":"2016","unstructured":"Almeida, A. R. et al. Delta one T cells for immunotherapy of chronic lymphocytic leukemia: clinical-grade expansion\/differentiation and preclinical proof of concept. Clin. Cancer Res. 22, 5795\u20135804 (2016).","journal-title":"Clin. Cancer Res."},{"key":"69538_CR31","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/2326-6066.CIR-18-0647","volume":"7","author":"B Di Lorenzo","year":"2019","unstructured":"Di Lorenzo, B. et al. Broad cytotoxic targeting of acute myeloid leukemia by polyclonal delta one T cells. Cancer Immunol. Res. 7, 552\u2013558 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"69538_CR32","doi-asserted-by":"publisher","first-page":"e005400","DOI":"10.1136\/jitc-2022-005400","volume":"10","author":"D S\u00e1nchez Mart\u00ednez","year":"2022","unstructured":"S\u00e1nchez Mart\u00ednez, D. et al. Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia. J. Immunother. Cancer 10, e005400 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"69538_CR33","doi-asserted-by":"publisher","unstructured":"Mensurado, S. et al. CD155\/PVR determines Acute Myeloid Leukemia targeting by Delta One T cells. Blood J. 143 https:\/\/doi.org\/10.1182\/blood.2023022992. (2024)","DOI":"10.1182\/blood.2023022992"},{"key":"69538_CR34","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1172\/JCI24480","volume":"115","author":"L Gattinoni","year":"2005","unstructured":"Gattinoni, L. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J. Clin. Investig. 115, 1616\u20131626 (2005).","journal-title":"J. Clin. Investig."},{"key":"69538_CR35","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1172\/JCI32103","volume":"118","author":"C Berger","year":"2008","unstructured":"Berger, C. et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Investig. 118, 294\u2013305 (2008).","journal-title":"J. Clin. Investig."},{"key":"69538_CR36","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.4110\/in.2018.18.e33","volume":"18","author":"S Kang","year":"2018","unstructured":"Kang, S., Brown, H. M. & Hwang, S. Direct antiviral mechanisms of interferon-gamma. Immune Netw 18, e33 (2018).","journal-title":"Immune Netw"},{"key":"69538_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2014.1003011","volume":"4","author":"F Guerville","year":"2015","unstructured":"Guerville, F. et al. TCR-dependent sensitization of human \u03b3\u03b4 T cells to non-myeloid IL-18 in cytomegalovirus and tumor stress surveillance. OncoImmunology 4, 1\u201313 (2015).","journal-title":"OncoImmunology"},{"key":"69538_CR38","doi-asserted-by":"publisher","unstructured":"Kaminski, H. et al. Characterization of a unique \u03b3\u03b4 T-cell subset as a specific marker of cytomegalovirus infection severity. J. Infect. Dis. https:\/\/doi.org\/10.1093\/infdis\/jiaa400. (2020).","DOI":"10.1093\/infdis\/jiaa400"},{"key":"69538_CR39","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/ni.2394","volume":"13","author":"CR Willcox","year":"2012","unstructured":"Willcox, C. R. et al. Cytomegalovirus and tumor stress surveillance by binding of a human \u03b3\u03b4 T cell antigen receptor to endothelial protein C receptor. Nat. Immunol. 13, 872\u2013879 (2012).","journal-title":"Nat. Immunol."},{"key":"69538_CR40","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1073\/pnas.1621052114","volume":"114","author":"R Marlin","year":"2017","unstructured":"Marlin, R. et al. Sensing of cell stress by human \u03b3\u03b4 TCR-dependent recognition of annexin A2. Proc. Natl. Acad. Sci. USA 114, 3163\u20133168 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"69538_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.00929","volume":"9","author":"AE Sim\u00f5es","year":"2018","unstructured":"Sim\u00f5es, A. E., Di Lorenzo, B. & Silva-Santos, B. Molecular determinants of target cell recognition by human \u03b3\u03b4 T cells. Front. Immunol. 9, 1\u20137 (2018).","journal-title":"Front. Immunol."},{"key":"69538_CR42","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.3389\/fimmu.2019.01148","volume":"10","author":"L Amini","year":"2019","unstructured":"Amini, L. et al. Comprehensive characterization of a next-generation antiviral T-cell product and feasibility for application in immunosuppressed transplant patients. Front. Immunol. 10, 1148 (2019).","journal-title":"Front. Immunol."},{"key":"69538_CR43","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1111\/ajt.13795","volume":"16","author":"I Ferrandiz","year":"2016","unstructured":"Ferrandiz, I. et al. Impact of early blood transfusion after kidney transplantation on the incidence of donor-specific anti-LA Antibodies. Am. J. Transplant. 16, 2661\u20132669 (2016).","journal-title":"Am. J. Transplant."},{"key":"69538_CR44","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S0009-9236(98)90066-2","volume":"64","author":"T Varis","year":"1998","unstructured":"Varis, T., Kaukonen, K.-M., Kivist\u00f6, K. T. & Neuvonen, P. J. Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole*. Clin. Pharmacol. Ther. 64, 363\u2013368 (1998).","journal-title":"Clin. Pharmacol. Ther."},{"key":"69538_CR45","first-page":"1","volume":"1","author":"M Jarque","year":"2020","unstructured":"Jarque, M. et al. Cellular immunity to predict the risk of cytomegalovirus infection in kidney transplantation: a prospective, interventional, multicenter clinical trial. Clin. Infect. Dis. 1, 1\u201311 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"69538_CR46","first-page":"321er1","volume":"8","author":"PJ Hanley","year":"2016","unstructured":"Hanley, P. J. et al. Erratum for the research article: \u201cCMV-specific T cells generated from na\u00efve T cells recognize atypical epitopes and may be protective in vivo\u201d by P. J. Hanley, J. J. Melenhorst, S. Nikiforow, P. Scheinberg, J. W. Blaney, G. Demmler-Harrison, C. R. Cruz. Sci. Transl. Med. 8, 321er1\u2013321er1 (2016).","journal-title":"Sci. Transl. Med."},{"key":"69538_CR47","doi-asserted-by":"publisher","first-page":"10894","DOI":"10.1128\/JVI.01477-14","volume":"88","author":"SE Jackson","year":"2014","unstructured":"Jackson, S. E., Mason, G. M., Okecha, G., Sissons, J. G. P. & Wills, M. R. Diverse specificities, phenotypes, and antiviral activities of cytomegalovirus-specific CD8+ T Cells. J. Virol. 88, 10894\u201310908 (2014).","journal-title":"J. Virol."},{"key":"69538_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcimb.2020.00275","volume":"10","author":"CJ Houldcroft","year":"2020","unstructured":"Houldcroft, C. J. et al. Assessing Anti-HCMV cell mediated immune responses in transplant recipients and healthy controls using a novel functional assay. Front. Cell. Infect. Microbiol. 10, 1\u201321 (2020).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"69538_CR49","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/j.1348-0421.1996.tb01103.x","volume":"40","author":"M Watanabe","year":"1996","unstructured":"Watanabe, M., Ito, M., Kamiya, H. & Sakurai, M. Adherence of peripheral blood leukocytes to cytomegalovirus-infected fibroblasts. Microbiol. Immunol. 40, 519\u2013523 (1996).","journal-title":"Microbiol. Immunol."},{"key":"69538_CR50","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.4049\/jimmunol.160.7.3143","volume":"160","author":"WJ Waldman","year":"1998","unstructured":"Waldman, W. J., Knight, D. A. & Huang, E. H. An in vitro model of T cell activation by autologous cytomegalovirus (CMV)-infected human adult endothelial cells: contribution of CMV-enhanced endothelial ICAM-1. J. Immunol. 160, 3143\u20133151 (1998).","journal-title":"J. Immunol."},{"key":"69538_CR51","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1084\/jem.187.10.1681","volume":"187","author":"CC Leong","year":"1998","unstructured":"Leong, C. C. et al. Modulation of natural killer cell cytotoxicity in human cytomegalovirus infection: the role of endogenous class I major histocompatibility complex and a viral class I homolog. J. Exp. Med. 187, 1681\u20131687 (1998).","journal-title":"J. Exp. Med."},{"key":"69538_CR52","doi-asserted-by":"crossref","unstructured":"Siegers, G. M. Integral roles for integrins in \u03b3\u03b4 T. Front. Immunol. 9, 521 (2018).","DOI":"10.3389\/fimmu.2018.00521"},{"key":"69538_CR53","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1086\/655472","volume":"202","author":"PJ van de Berg","year":"2010","unstructured":"van de Berg, P. J. et al. Human cytomegalovirus induces systemic immune activation characterized by a Type 1 Cytokine signature. J. Infect. Dis. 202, 690\u2013699 (2010).","journal-title":"J. Infect. Dis."},{"key":"69538_CR54","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13682","volume":"23","author":"AH Karaba","year":"2021","unstructured":"Karaba, A. H. et al. Interleukin-18 and tumor necrosis factor-\u03b1 are elevated in solid organ transplant recipients with possible cytomegalovirus end-organ disease. Transpl. Infect. Dis. 23, e13682 (2021).","journal-title":"Transpl. Infect. Dis."},{"key":"69538_CR55","doi-asserted-by":"publisher","first-page":"6488","DOI":"10.4049\/jimmunol.171.12.6488","volume":"171","author":"JE Dalton","year":"2003","unstructured":"Dalton, J. E., Pearson, J., Scott, P. & Carding, S. R. The interaction of \u03b3\u03b4 T cells with activated macrophages is a property of the V\u03b31 subset. J. Immunol. 171, 6488\u20136494 (2003).","journal-title":"J. Immunol."},{"key":"69538_CR56","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1165\/rcmb.2008-0090TR","volume":"39","author":"MI Hirsh","year":"2008","unstructured":"Hirsh, M. I. & Junger, W. G. Roles of heat shock proteins and \u03b3\u03b4T cells in inflammation. Am. J. Respir. Cell Mol. Biol. 39, 509\u2013513 (2008).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"69538_CR57","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1053\/bbmt.1999.v5.pm10465102","volume":"5","author":"WR Drobyski","year":"1999","unstructured":"Drobyski, W. R., Majewski, D. & Hanson, G. Graft-facilitating doses of ex vivo activated \u03b3\u03b4 T cells do not cause lethal murine graft-vs.-host disease. Biol. Blood Marrow Transplant. 5, 222\u2013230 (1999).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"69538_CR58","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1681\/ASN.2013101052","volume":"25","author":"T Bachelet","year":"2014","unstructured":"Bachelet, T. et al. Cytomegalovirus-responsive gd T Cells: novel effector cells in antibody-mediated kidney allograft microcirculation lesions. J. Am. Soc. Nephrol. 25, 2471\u20132482 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"69538_CR59","doi-asserted-by":"publisher","first-page":"12859","DOI":"10.3389\/ti.2025.12859","volume":"38","author":"X Charmetant","year":"2025","unstructured":"Charmetant, X. et al. T cells\u2019 role in donor-specific antibody generation: insights from transplant recipients and experimental models. Transpl. Int. 38, 12859 (2025).","journal-title":"Transpl. Int."},{"key":"69538_CR60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010785","volume":"20","author":"N Yared","year":"2024","unstructured":"Yared, N. et al. Long-lived central memory \u03b3\u03b4 T cells confer protection against murine cytomegalovirus reinfection. PLOS Pathog 20, e1010785 (2024).","journal-title":"PLOS Pathog"},{"key":"69538_CR61","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1681\/ASN.2020121753","volume":"33","author":"H Kaminski","year":"2022","unstructured":"Kaminski, H. et al. mTOR inhibitors prevent CMV infection through the restoration of functional ab and gd T cells in kidney transplantation. J. Am. Soc. Nephrol. 33, 121\u2013137 (2022).","journal-title":"J. Am. Soc. Nephrol."},{"key":"69538_CR62","doi-asserted-by":"publisher","first-page":"W242","DOI":"10.1093\/nar\/gky354","volume":"46","author":"JP Concordet","year":"2018","unstructured":"Concordet, J. P. & Haeussler, M. CRISPOR: intuitive guide selection for CRISPR\/Cas9 genome editing experiments and screens. Nucleic Acids Res. 46, W242\u2013W245 (2018).","journal-title":"Nucleic Acids Res."},{"key":"69538_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1012-2","volume":"17","author":"M Haeussler","year":"2016","unstructured":"Haeussler, M. et al. Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR. Genome Biol. 17, 148 (2016).","journal-title":"Genome Biol."},{"key":"69538_CR64","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","volume":"34","author":"JG Doench","year":"2016","unstructured":"Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol. 34, 184\u2013191 (2016).","journal-title":"Nat. Biotechnol."},{"key":"69538_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11955-7","volume":"10","author":"J Tycko","year":"2019","unstructured":"Tycko, J. et al. Mitigation of off-target toxicity in CRISPR-Cas9 screens for essential non-coding elements. Nat. Commun. 10, 4063 (2019).","journal-title":"Nat. Commun."},{"key":"69538_CR66","doi-asserted-by":"crossref","unstructured":"Oh, S. A., Seki, A. & Rutz, S. Ribonucleoprotein transfection for CRISPR\/Cas9-mediated gene knockout in primary T cells. Curr. Protoc. Immunol. 124, e69 (2019).","DOI":"10.1002\/cpim.69"},{"key":"69538_CR67","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1038\/sj.ki.5000277","volume":"69","author":"SC Satchell","year":"2006","unstructured":"Satchell, S. C. et al. Conditionally immortalized human glomerular endothelial cells expressing fenestrations in response to VEGF. Kidney Int. 69, 1633\u20131640 (2006).","journal-title":"Kidney Int."},{"key":"69538_CR68","doi-asserted-by":"publisher","unstructured":"Baer, A. & Kehn-Hall, K. Viral concentration determination through plaque assays: using traditional and novel overlay systems. J. Vis. Exp. 1\u201310 https:\/\/doi.org\/10.3791\/52065. (2014).","DOI":"10.3791\/52065"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69538-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69538-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69538-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T16:03:51Z","timestamp":1774541031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69538-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["69538"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-69538-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"24 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.S.-S. was a co-inventor of the DOT cell technology now owned by Takeda, which supports his work via a sponsored research agreement. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2847"}}